GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Operating Margin %

Nanomix (Nanomix) Operating Margin % : 0.00% (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Nanomix's Operating Income for the three months ended in Dec. 2022 was $-1.86 Mil. Nanomix's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Nanomix's Operating Margin % for the quarter that ended in Dec. 2022 was 0.00%.

The historical rank and industry rank for Nanomix's Operating Margin % or its related term are showing as below:


NNMX's Operating Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.36
* Ranked among companies with meaningful Operating Margin % only.

Nanomix's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Nanomix's Operating Income for the three months ended in Dec. 2022 was $-1.86 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-8.40 Mil.


Nanomix Operating Margin % Historical Data

The historical data trend for Nanomix's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Operating Margin % Chart

Nanomix Annual Data
Trend Dec20 Dec21 Dec22
Operating Margin %
-8,176.67 - -56,246.67

Nanomix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - -10,646.67 - -

Competitive Comparison of Nanomix's Operating Margin %

For the Medical Devices subindustry, Nanomix's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nanomix's Operating Margin % falls into.



Nanomix Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nanomix's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-8.437 / 0.015
=-56,246.67 %

Nanomix's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=-1.861 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanomix  (OTCPK:NNMX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nanomix Operating Margin % Related Terms

Thank you for viewing the detailed overview of Nanomix's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338

Nanomix (Nanomix) Headlines

From GuruFocus

Nanomix Announces Upgrade to OTCQB� Venture Market

By PurpleRose PurpleRose 07-12-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 05-26-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 06-14-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 07-04-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-22-2022

Nanomix Initiates New Clinical Study for the eLab S1 Panel

By GuruFocusNews GuruFocusNews 06-22-2022

Nanomix Initiates New Clinical Study for the eLab S1 Panel

By GuruFocusNews GuruFocusNews 07-02-2022